PHARMING GROUP NV (PHGN.DE) Fundamental Analysis & Valuation

FRA:PHGN • NL0010391025

Current stock price

1.428 EUR
+0.05 (+3.33%)
Last:

This PHGN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. PHGN.DE Profitability Analysis

1.1 Basic Checks

  • PHGN had negative earnings in the past year.
  • PHGN had a positive operating cash flow in the past year.
  • In multiple years PHGN reported negative net income over the last 5 years.
  • In multiple years PHGN reported negative operating cash flow during the last 5 years.
PHGN.DE Yearly Net Income VS EBIT VS OCF VS FCFPHGN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.57%, PHGN is in the better half of the industry, outperforming 69.14% of the companies in the same industry.
  • PHGN has a better Return On Equity (1.03%) than 72.84% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 6.62%, PHGN is in the better half of the industry, outperforming 79.01% of the companies in the same industry.
Industry RankSector Rank
ROA 0.57%
ROE 1.03%
ROIC 6.62%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
PHGN.DE Yearly ROA, ROE, ROICPHGN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin of PHGN (0.76%) is better than 70.37% of its industry peers.
  • In the last couple of years the Profit Margin of PHGN has declined.
  • The Operating Margin of PHGN (9.61%) is better than 79.01% of its industry peers.
  • PHGN's Operating Margin has declined in the last couple of years.
  • PHGN's Gross Margin of 87.90% is amongst the best of the industry. PHGN outperforms 82.72% of its industry peers.
  • In the last couple of years the Gross Margin of PHGN has remained more or less at the same level.
Industry RankSector Rank
OM 9.61%
PM (TTM) 0.76%
GM 87.9%
OM growth 3Y19.98%
OM growth 5Y-24.69%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
PHGN.DE Yearly Profit, Operating, Gross MarginsPHGN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PHGN.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHGN is destroying value.
  • The number of shares outstanding for PHGN has been increased compared to 1 year ago.
  • Compared to 5 years ago, PHGN has more shares outstanding
  • PHGN has a better debt/assets ratio than last year.
PHGN.DE Yearly Shares OutstandingPHGN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
PHGN.DE Yearly Total Debt VS Total AssetsPHGN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • PHGN has an Altman-Z score of 3.96. This indicates that PHGN is financially healthy and has little risk of bankruptcy at the moment.
  • PHGN has a better Altman-Z score (3.96) than 62.96% of its industry peers.
  • PHGN has a debt to FCF ratio of 2.15. This is a good value and a sign of high solvency as PHGN would need 2.15 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 2.15, PHGN belongs to the best of the industry, outperforming 87.65% of the companies in the same industry.
  • PHGN has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
  • PHGN's Debt to Equity ratio of 0.39 is in line compared to the rest of the industry. PHGN outperforms 55.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Altman-Z 3.96
ROIC/WACC0.94
WACC7.07%
PHGN.DE Yearly LT Debt VS Equity VS FCFPHGN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • PHGN has a Current Ratio of 2.59. This indicates that PHGN is financially healthy and has no problem in meeting its short term obligations.
  • PHGN's Current ratio of 2.59 is in line compared to the rest of the industry. PHGN outperforms 50.62% of its industry peers.
  • A Quick Ratio of 2.03 indicates that PHGN has no problem at all paying its short term obligations.
  • PHGN has a Quick ratio (2.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.03
PHGN.DE Yearly Current Assets VS Current LiabilitesPHGN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. PHGN.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 111.11% over the past year.
  • The earnings per share for PHGN have been decreasing by -48.41% on average. This is quite bad
  • The Revenue has grown by 26.56% in the past year. This is a very strong growth!
  • The Revenue has been growing by 12.13% on average over the past years. This is quite good.
EPS 1Y (TTM)111.11%
EPS 3Y-41.82%
EPS 5Y-48.41%
EPS Q2Q%60%
Revenue 1Y (TTM)26.56%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%

3.2 Future

  • Based on estimates for the next years, PHGN will show a very strong growth in Earnings Per Share. The EPS will grow by 157.07% on average per year.
  • Based on estimates for the next years, PHGN will show a quite strong growth in Revenue. The Revenue will grow by 12.57% on average per year.
EPS Next Y1671.6%
EPS Next 2Y376.03%
EPS Next 3Y187.89%
EPS Next 5Y157.07%
Revenue Next Year8.86%
Revenue Next 2Y5.64%
Revenue Next 3Y0.12%
Revenue Next 5Y12.57%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
PHGN.DE Yearly Revenue VS EstimatesPHGN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
PHGN.DE Yearly EPS VS EstimatesPHGN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.1 -0.1 0.2

More info and screens

Find the best growth stocksShow best growing peers

5

4. PHGN.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Forward Earnings ratio of 47.13 indicates a quite expensive valuation of PHGN.
  • Based on the Price/Forward Earnings ratio, PHGN is valued a bit cheaper than the industry average as 77.78% of the companies are valued more expensively.
  • PHGN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.24.
Industry RankSector Rank
PE N/A
Fwd PE 47.13
PHGN.DE Price Earnings VS Forward Price EarningsPHGN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHGN is valued a bit cheaper than 77.78% of the companies in the same industry.
  • PHGN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PHGN is cheaper than 87.65% of the companies in the same industry.
Industry RankSector Rank
P/FCF 21.86
EV/EBITDA 23.17
PHGN.DE Per share dataPHGN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as PHGN's earnings are expected to grow with 187.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y376.03%
EPS Next 3Y187.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHGN.DE Dividend Analysis

5.1 Amount

  • No dividends for PHGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHGN.DE Fundamentals: All Metrics, Ratios and Statistics

PHARMING GROUP NV

FRA:PHGN (4/24/2026, 7:00:00 PM)

1.428

+0.05 (+3.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners21.67%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap1.01B
Revenue(TTM)376.13M
Net Income(TTM)2.85M
Analysts88.57
Price Target2.23 (56.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)532.06%
Min EPS beat(2)-6.76%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)286.26%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)81.54%
EPS beat(12)5
Avg EPS beat(12)48.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-1.68%
Max Revenue beat(2)1.11%
Revenue beat(4)3
Avg Revenue beat(4)5.37%
Min Revenue beat(4)-1.68%
Max Revenue beat(4)13.37%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)7
Avg Revenue beat(12)0.29%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.48%
PT rev (3m)1.37%
EPS NQ rev (1m)333.33%
EPS NQ rev (3m)-78.33%
EPS NY rev (1m)-10.42%
EPS NY rev (3m)-9.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 47.13
P/S 3.14
P/FCF 21.86
P/OCF 21.56
P/B 4.26
P/tB 8.33
EV/EBITDA 23.17
EPS(TTM)0
EYN/A
EPS(NY)0.03
Fwd EY2.12%
FCF(TTM)0.07
FCFY4.57%
OCF(TTM)0.07
OCFY4.64%
SpS0.46
BVpS0.34
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 0.57%
ROE 1.03%
ROCE 9.41%
ROIC 6.62%
ROICexc 12.41%
ROICexgc 36.59%
OM 9.61%
PM (TTM) 0.76%
GM 87.9%
FCFM 14.34%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y56.06%
ROICexgc growth 5Y-23.52%
ROICexc growth 3Y34.74%
ROICexc growth 5Y-22.16%
OM growth 3Y19.98%
OM growth 5Y-24.69%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Debt/EBITDA 2.26
Cap/Depr 6.73%
Cap/Sales 0.2%
Interest Coverage 5.83
Cash Conversion 115.52%
Profit Quality 1892.42%
Current Ratio 2.59
Quick Ratio 2.03
Altman-Z 3.96
F-Score6
WACC7.07%
ROIC/WACC0.94
Cap/Depr(3y)6.96%
Cap/Depr(5y)24.22%
Cap/Sales(3y)0.36%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)111.11%
EPS 3Y-41.82%
EPS 5Y-48.41%
EPS Q2Q%60%
EPS Next Y1671.6%
EPS Next 2Y376.03%
EPS Next 3Y187.89%
EPS Next 5Y157.07%
Revenue 1Y (TTM)26.56%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%
Revenue Next Year8.86%
Revenue Next 2Y5.64%
Revenue Next 3Y0.12%
Revenue Next 5Y12.57%
EBIT growth 1Y519.14%
EBIT growth 3Y46.74%
EBIT growth 5Y-15.55%
EBIT Next Year4.35%
EBIT Next 3Y34.62%
EBIT Next 5Y57.73%
FCF growth 1Y2182.32%
FCF growth 3Y38.11%
FCF growth 5Y-4.61%
OCF growth 1Y3147.8%
OCF growth 3Y34.55%
OCF growth 5Y-8.14%

PHARMING GROUP NV / PHGN.DE Fundamental Analysis FAQ

What is the fundamental rating for PHGN stock?

ChartMill assigns a fundamental rating of 5 / 10 to PHGN.DE.


Can you provide the valuation status for PHARMING GROUP NV?

ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHGN.DE). This can be considered as Fairly Valued.


How profitable is PHARMING GROUP NV (PHGN.DE) stock?

PHARMING GROUP NV (PHGN.DE) has a profitability rating of 4 / 10.


What is the financial health of PHARMING GROUP NV (PHGN.DE) stock?

The financial health rating of PHARMING GROUP NV (PHGN.DE) is 7 / 10.